Thrombosis research最新文献

{"title":"Effect of lupus anti-coagulant and antiphospholipid antibodies on clot waveform analysis parameters","authors":"Jing Yuan Tan, Wan Hui Wong, Wenshan Liu, Chi Kiat Yeo, Guan Hao Goh, Hong Kheng Neo, Choo Kheng Tan, Heng Joo Ng, Chuen Wen Tan","doi":"10.1016/j.thromres.2025.109268","DOIUrl":"10.1016/j.thromres.2025.109268","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"247 ","pages":"Article 109268"},"PeriodicalIF":3.7,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143142834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in menstrual bleeding management during acute venous thromboembolism treatment: A review of UK practice and a call for clinical studies","authors":"Eman Hassan ,&nbsp;David Sutton ,&nbsp;Richard J Buka ,&nbsp;Gillian Lowe ,&nbsp;Taran Nandra ,&nbsp;Nkemdirim Jacob ,&nbsp;Lucy Rose ,&nbsp;Yasir Alhamdi ,&nbsp;HaemSTAR Collaborators,&nbsp;Phillip L.R. Nicolson","doi":"10.1016/j.thromres.2025.109258","DOIUrl":"10.1016/j.thromres.2025.109258","url":null,"abstract":"<div><h3>Background</h3><div>Heavy menstrual bleeding (HMB) is a significant clinical burden for premenopausal individuals treated with anticoagulation for acute venous thromboembolism (VTE). Despite its prevalence, HMB management remains poorly studied, with wide variation in clinical practice.</div></div><div><h3>Objectives</h3><div>The current study aimed to explore current UK practices in managing HMB in anticoagulated individuals and identify areas requiring clinical research to address disparities.</div></div><div><h3>Methods</h3><div>A national survey was conducted among haematology consultants and consultant clinical pharmacists managing anticoagulated patients. The survey focused on management strategies, including anticoagulant selection, use of tranexamic acid (TXA), contraceptive options, and anticoagulation interruption.</div></div><div><h3>Results and conclusion</h3><div>Responses were collected from 102 participants, across the UK. Apixaban was the preferred anticoagulant for patients with HMB, followed by LMWH then dabigatran. Timing of TXA initiation varied widely between respondents, with (35.3 %) prescribing it any time after anticoagulation initiation, (11.8 %) delaying TXA use for 3 months, and (7.8 %) would not give it at all. (47.1 %) of respondents advise to discontinue oestrogen containing contraceptives in patients with acute VTE. Almost all respondents never or rarely stop anticoagulation for a patient with HMB and recent VTE ≤4 weeks. (62.7 %) of respondents showed their willingness to participate in clinical studies to study TXA use in the setting of acute VTE ≤4 weeks in anticoagulated individuals.</div><div>This study highlights significant variations in HMB management during anticoagulation for acute VTE. Disparities raise concerns about health inequities and underscore the urgent need for prospective clinical trials to improve patient outcomes.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"247 ","pages":"Article 109258"},"PeriodicalIF":3.7,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is all collagen the same for platelet testing? Editorial on “Platelet collagen receptors and their role in modulating platelet adhesion patterns and activation on alternatively processed collagen substrates”","authors":"Kristina Mott","doi":"10.1016/j.thromres.2025.109255","DOIUrl":"10.1016/j.thromres.2025.109255","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"247 ","pages":"Article 109255"},"PeriodicalIF":3.7,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of warfarin management following transfer from an anticoagulation clinic to primary care","authors":"Alex Predy ,&nbsp;Ben Vandermeer ,&nbsp;Theresa Eberhardt ,&nbsp;Tammy J. Bungard","doi":"10.1016/j.thromres.2025.109257","DOIUrl":"10.1016/j.thromres.2025.109257","url":null,"abstract":"<div><h3>Background</h3><div>Advances in alternative oral anticoagulants has reduced use and clinician comfort with warfarin. Our specialty anticoagulation clinic (AC) operates at maximum capacity and must transfer patients to accept new referrals.</div></div><div><h3>Objectives</h3><div>To compare time within therapeutic range (TTR) during 6 months of AC care versus following transfer to primary care for a minimum of 6 months and to a maximum of 24 months. Secondarily, to compare frequency of INR assessments, proportion of INRs ≤1.5 and &gt; 5, and rates of bleeding and thromboembolic events post-transfer to primary care.</div></div><div><h3>Methods</h3><div>Mixed retrospective chart review and administrative audit with a before-after study design for patients managed by the University of Alberta's AC for at least 6 months that were transferred to primary care.</div></div><div><h3>Results</h3><div>177 (27.7 %) patients were included, managed by the AC for 3.4 years (1.3, 7.9). TTR declined during the first 6 months post-transfer with AC care achieving 69.2 % and primary care 64.5 % (p = 0.02) and when compared to the 24-month interval (69.2 % vs 63.4 %; respectively; p = 0.003). A shorter interval between INRs in AC care was observed (28.9 (24.4) vs 34.5 (31.7) days, respectively; p = 0.0004). Similar numbers of critical INRs occurred between groups, whereas more INRs ≤1.5 occurred in primary care (7.3 % vs 4.7 %, respectively; p = 0.0003). Bleeding and thromboembolic event rates were balanced following transfer to primary care with both occurring at 9.4 % per patient year.</div></div><div><h3>Conclusion</h3><div>A decline in anticoagulation control after transfer to primary care was observed, which appeared to be driven by a greater proportion of subtherapeutic INRs.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"247 ","pages":"Article 109257"},"PeriodicalIF":3.7,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143011297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tissue factor-bearing extracellular vesicles, procoagulant phospholipids and D-dimer as potential biomarkers for venous thromboembolism in patients with newly diagnosed multiple myeloma: A comprehensive analysis","authors":"S. Charles ,&nbsp;T. Fatrara ,&nbsp;T. Bouriche ,&nbsp;A. Bonifay ,&nbsp;T. Lecompte ,&nbsp;F. Dignat-George ,&nbsp;B. Tardy ,&nbsp;C. Frere ,&nbsp;R. Lacroix ,&nbsp;E. Chalayer","doi":"10.1016/j.thromres.2025.109256","DOIUrl":"10.1016/j.thromres.2025.109256","url":null,"abstract":"<div><h3>Background</h3><div>Candidate biomarkers to improve venous thromboembolism (VTE) risk prediction in patients with newly diagnosed multiple myeloma (MM) undergoing anti-myeloma therapy include tissue factor-bearing microvesicles (MV-TF), procoagulant phospholipids (procoag-PPL), and D-dimer.</div></div><div><h3>Objective</h3><div>We aimed to determine the levels of MV-TF, procoag-PPL, and D-dimer at baseline and during initial anti-myeloma therapy and their association with the risk of VTE.</div></div><div><h3>Methods</h3><div>This prospective, longitudinal, observational study included 71 patients with newly diagnosed MM who were eligible for anti-myeloma therapy. Circulating MV-TF levels were measured using a functional method adapted from the Chapel Hill TF-dependent Factor Xa generation assay, and PPL and D-dimer levels with commercially available assays. The three biomarkers were measured at baseline and throughout treatment.</div></div><div><h3>Results</h3><div>Baseline and on-treatment MV-TF levels were higher in patients who developed VTE compared to those who did not (4.25 <em>versus</em> 2.75 fM at baseline, <em>p</em> = 0.047 and 6.5 <em>versus</em> 1.5 fM during treatment, <em>p</em> = 0.001). Baseline and on-treatment Procoag-PPL clotting times did not differ between the groups. Baseline D-dimer levels tended to be higher in patients who developed VTE than in those who did not (1.38 <em>versus</em> 0.7 μg/mL, <em>p</em> = 0.08). During treatment, D-dimer levels were significantly higher in the VTE group than in the non-VTE group (1.08 <em>versus</em> 0.44 μg/mL, <em>p</em> = 0.008).</div></div><div><h3>Conclusion</h3><div>Our results suggest that MV-TF and D-dimer levels may help to refine VTE risk prediction in nMM patients undergoing anti-myeloma therapy. Adequately sized studies including patients receiving new MM therapies are needed to confirm this hypothesis.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"247 ","pages":"Article 109256"},"PeriodicalIF":3.7,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143011533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulation stewardship in the ambulatory settings of long-term care and rehabilitation - A multi-centric descriptive pilot study","authors":"Maria Macoviciuc ,&nbsp;Christina Furneri ,&nbsp;Léa Callens ,&nbsp;Bao Ling Wei ,&nbsp;Helen Mantzanis ,&nbsp;Nikki Kampouris ,&nbsp;Maral Koolian ,&nbsp;Vincent Dagenais-Beaulé ,&nbsp;Ryan S. Kerzner","doi":"10.1016/j.thromres.2024.109238","DOIUrl":"10.1016/j.thromres.2024.109238","url":null,"abstract":"<div><h3>Background</h3><div>Anticoagulants have consistently emerged as the leading cause of adverse drug events in both inpatient and outpatient settings. While literature on anticoagulation stewardship programs (ACSP) exists for hospital settings, there is a paucity of data in long-term care and rehabilitation settings.</div></div><div><h3>Objective</h3><div>Assess the feasibility of a pharmacist led ACSP in the ambulatory healthcare settings of long-term care facilities (LTC) and rehabilitation centers (RC).</div></div><div><h3>Methods</h3><div>We conducted a prospective pilot project in 3 rehabilitation centers and 7 long-term care facilities. Patients were selected over 5 months in 2023. Patient and anticoagulant prescription-related characteristics were collected. The primary feasibility outcome was the proportion of anticoagulant prescription reviews leading to a pharmacist intervention.</div></div><div><h3>Results</h3><div>A total of 411 patients were enrolled. Common indications for anticoagulants were atrial fibrillation (<em>n</em> = 255, 62.0 %), medical thromboprophylaxis (<em>n</em> = 52, 12.7 %) and venous thromboembolism (<em>n</em> = 53, 12.9 %). Direct oral anticoagulants (DOAC) were most frequently prescribed (<em>n</em> = 309, 75.2 %). Of 411 prescription reviews, 93 led to at least one intervention (22.6 %), for a total of 100 interventions. Interventions mainly concerned laboratory ordering (<em>n</em> = 29) and DOAC dose adjustment (<em>n</em> = 24). Baseline anticoagulant characteristics and outcomes varied by healthcare setting.</div></div><div><h3>Conclusion</h3><div>Expanding ACSP into outpatient LTC and RC settings is feasible. ACSP should include both therapeutic and thromboprophylactic anticoagulants. Additional research is warranted to evaluate the viability of ongoing ACSP monitoring, and more extensive prospective studies are required to assess clinical outcomes effectively.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109238"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the simplified Pulmonary Embolism Severity Index (sPESI) score and hospitalization in emergency department patients diagnosed with pulmonary embolism","authors":"Pranav Tandon ,&nbsp;Cameron Thompson ,&nbsp;Karen Li ,&nbsp;Shelley L. McLeod ,&nbsp;Kerstin de Wit ,&nbsp;Keerat Grewal","doi":"10.1016/j.thromres.2024.109234","DOIUrl":"10.1016/j.thromres.2024.109234","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109234"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding European patterns of deprescribing antithrombotic medication during end-of-life care in patients with cancer","authors":"E.S.L. Martens ,&nbsp;D. Becker ,&nbsp;C. Abele ,&nbsp;D. Abbel ,&nbsp;W.P. Achterberg ,&nbsp;J.J. Bax ,&nbsp;L. Bertoletti ,&nbsp;M.E. Edwards ,&nbsp;C. Font ,&nbsp;A. Gava ,&nbsp;J. Goedegebuur ,&nbsp;A.A. Højen ,&nbsp;M.V. Huisman ,&nbsp;M.J.H.A. Kruip ,&nbsp;I. Mahé ,&nbsp;S.P. Mooijaart ,&nbsp;M. Pearson ,&nbsp;K. Seddon ,&nbsp;S. Szmit ,&nbsp;S.I.R. Noble ,&nbsp;S.V. Konstantinides","doi":"10.1016/j.thromres.2024.109205","DOIUrl":"10.1016/j.thromres.2024.109205","url":null,"abstract":"<div><h3>Background</h3><div>Even though antithrombotic therapy (ATT) probably has little or even negative effect on the well-being of patients with cancer near the end of life, it is often continued until death, possibly leading to excess bleeding complications, increased disease burden, reduced quality of life and higher healthcare costs.</div></div><div><h3>Aim</h3><div>To explore and describe European practice patterns and perspectives of healthcare professionals from different disciplines and specialties on ATT in the end-of-life care (EOLC) of patients with cancer.</div></div><div><h3>Methods</h3><div>We performed a two-week international cross-sectional survey study using flash-mob research methodology. Eligible were healthcare professionals from different institutions across Europe, who prescribed ATT and/or dealt with EOLC of patients with cancer. The survey comprised three parts, including a series of choice sets (hypothetical scenarios involving a set of characteristics changing in level [e.g., high vs. low thrombotic risk]) on ATT management in EOLC. The discrete choice experiment analysis was conducted using multinomial logistic regression.</div></div><div><h3>Results</h3><div>Out of 467 pre-registrants, 208 participated in the survey from 4 to 18 July 2023. The majority (53 %) considered a patient with cancer as in EOLC when life expectancy is below 3 months. Respondents reported seeing or treating 20 patients with cancer on ATT in EOLC per year (IQR 10–50). The median estimated frequency of considering ATT deprescription per healthcare professional was 10 times per year (IQR 4–10), while the frequency of actual deprescription was 5 times per year (IQR 2–10). Twenty percent of respondents had never deprescribed ATT in the context of EOLC. Across the eight choice sets, five respondents (2.7 %) found deprescribing inappropriate in any scenario. Deprescribing was more often considered in patients with poor ECOG-performance status, high bleeding risk and low-molecular-weight heparin use as opposed to oral ATT. Haemato-oncology and cardiovascular medicine specialists were more inclined to deprescribe antiplatelet therapy than other specialties.</div></div><div><h3>Conclusion</h3><div>Our study describes medical decision-making regarding ATT in EOLC of patients with cancer. Healthcare professionals' perspectives and practice patterns vary, and some preferences appear associated with the therapists' professional focus and region of practice.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109205"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142819282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exogenous Protein S inhibits pancreatic ductal adenocarcinoma","authors":"Teagan Prouse ,&nbsp;Kristina Larter ,&nbsp;Sonali Ghosh ,&nbsp;Narender Kumar ,&nbsp;Mohammad A. Mohammad ,&nbsp;Luis Del Valle ,&nbsp;Rinku Majumder ,&nbsp;Samarpan Majumder","doi":"10.1016/j.thromres.2024.109233","DOIUrl":"10.1016/j.thromres.2024.109233","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109233"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of discussions around left atrial appendage occlusion as a treatment option in patients on oral anticoagulation experiencing a major bleeding event","authors":"Amber Co ,&nbsp;Chloe Kazaglis ,&nbsp;Deborah DeCamillo,&nbsp;Brian Haymart,&nbsp;Brindha Rajakumar,&nbsp;Geoffrey D. Barnes","doi":"10.1016/j.thromres.2024.109239","DOIUrl":"10.1016/j.thromres.2024.109239","url":null,"abstract":"<div><h3>Background</h3><div>Guidelines recommend considering percutaneous left atrial appendage occlusion (LAAO) in patients with atrial fibrillation (AF) at moderate to high stroke risk and contraindications to long-term anticoagulation. Discontinuation of anticoagulation in this patient population, without an alternative treatment option, may place patients at unnecessary risk. This study aimed to assess the prevalence of discussions around LAAO as a treatment option following major bleeding adverse events in patients on oral anticoagulation for AF and to identify the proportion of patients stopping anticoagulation without evidence of LAAO discussions.</div></div><div><h3>Methods</h3><div>From a single, large medical center in the United States, patients on an oral anticoagulant for AF and having at least one major bleeding adverse event, defined by the International Society on Thrombosis and Haemostasis, between January 2015 and October 2023 were identified within a quality improvement registry. Information about LAAO discussions, subsequent procedures, and permanent discontinuation of anticoagulation was assessed using the Electronic Medical Record Search Engine and manual electronic medical record reviews.</div></div><div><h3>Results</h3><div>A total of 222 patients experienced major bleeding (54.5 % male, 86.9 % white, median age 77 years, 58.6 % on warfarin). From this group, 283 major bleeds were documented (44.2 % gastrointestinal, 17.7 % intracranial). LAAO discussions were documented in 51 patients (23 %), with LAAO procedures performed in 9 of these patients (17.6 %). After the major bleed, 54 (24.3 %) patients permanently stopped anticoagulation. Of these patients, 18 (33.3 %) had LAAO discussions prior to discontinuation and only 1 (1.9 %) had LAAO implantation.</div></div><div><h3>Conclusions</h3><div>In patients experiencing a major bleed, less than a quarter had documented discussions about LAAO and over a quarter permanently stopped anticoagulation.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109239"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}